Summary
There is currently no approved vaccine for <i>Shigella</i> spp., a leading cause of diarrhea that are increasingly resistant to antimicrobials. <i>Shigella</i> vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal antibodies (mAbs) against candidate <i>Shigella</i> vaccine antigens using samples from a <i>Shigella flexneri</i> outbreak in a non-human primate (NHP) research facility. We found that antibodies targeting the <i>Shigella</i> O-antigen (O-Ag) can undergo significant affinity maturation (>10%) to acquire broad cross-reactivity across <i>S. flexneri</i> serotypes. We also found that the virulence-associated type III secretion system (T3SS) proteins IpaD and IpaB el
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.